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SOCS1 and SOCS3 are specific inhibitors for JAK tyrosine kinases. In this issue of Immunity, Babon et al.
(2012) discovered the inhibition mechanism of SOCS3 by employing nuclear magnetic resonance and
classical enzyme kinetics.Janus kinase (JAK), which is a key signal
transmitter of cytokines, has been shown
to be an attractive therapeutic target for
cancer and inflammatory diseases. Most
cytokines, including interleukins, inter-
ferons (IFNs), and hematopoietic growth
factors, activate JAKs. In mammals, the
JAK family comprises four members:
JAK1, JAK2, JAK3, and TYK2. JAK1,
JAK2, andTYK2appear to be ubiquitously
expressed, whereas JAK3 expression is
normally limited to hematopoietic cells.
Activated JAKs phosphorylate the asso-
ciated receptor cytoplasmic domains,
which then creates docking sites for
SH2-containing signaling proteins, includ-
ing signal transducers and activators of
transcription (STATs). The Ras-ERK and
PI3 kinase pathways are also activated
through JAKs. Aberrant activation of these
pathways is often observed in many
cancer and leukemic cells. Hyperactiva-
tion of the JAK-STAT pathway plays a
role in several immunological disorders
such as inflammatory diseases, autoim-
mune diseases, and allergy.
Several JAK2 inhibitors are under
development for the treatment of myelo-
proliferative neoplasias (MPN) and other
tumors. This is because constitutive acti-
vation of JAK2 was found in leukemias
and lymphomas (via formation of chi-meric proteins) and in MPN (via a
V617F mutation). JAK inhibitors are also
effective for tumors with constitutive
JAK-STAT pathway activation without
mutations. Therapeutic benefit from JAK
kinase inhibition has already been estab-
lished in rheumatoid arthritis (RA) with
the use of CP-690,550 (Tofacitinib), a
pan-JAK inhibitor. CP-690,550 was orig-
inally intended for organ transplantation
immunosuppression because it is a
potent inhibitor of JAK3, but has also
shown to have activity against JAK1
and JAK2. More recently, the selective
JAK1, JAK2 inhibitor, INCB028050, has
demonstrated efficacy in various rodent
models of RA, further demonstrating the
central role JAK kinases play in this
disease.
There is a natural inhibitor family for the
JAKs: the SOCS family of proteins (Alex-
ander and Hilton, 2004; Yoshimura et al.,
2007). Overexpression of these proteins
has been shown to effectively suppress
tumors and RA models (Yoshimura et al.,
2007). Thus, SOCS mimetics is a strategy
for developing therapeutics to these
diseases. However, a precise mechanism
of how SOCS inhibits JAK kinase activity
remains to be established. In this issue
of Immunity, Babon et al. (2012) suc-
ceeded in obtaining NMR spectrums ofJAK2 kinase domain and the SOCS3
complex, and, in combination with clas-
sical biochemical enzyme assays, they
discovered an unexpected mechanism
through which SOCS3 inhibits JAK kinase
activity.
The suppressor of cytokine signaling
(SOCS) protein family comprises eight
members (cytokine-inducible SH2 protein
[CIS] and SOCS1–SOCS7). The central
SH2 domain determines the target of
each SOCS and CIS protein. There is
a conserved sequence called extended
SH2 domain (ESS) adjacent to the SH2
domain, which is necessary for a high-
affinity binding of the SH2 domain to
the target phosphopeptides (Babon
et al., 2006; Yasukawa et al., 1999). The
SH2 domain (including ESS) of SOCS1
directly binds to the activation loop of
JAK (Yasukawa et al., 1999). While the
SH2 domains of CIS, SOCS2, and
SOCS3 bind to phosphorylated tyrosine
residues on activated cytokine receptors,
SOCS3 binds to gp130-related cytokine
receptors, including the phosphorylated
tyrosine 757 (Y757) residue of gp130, the
Y800 residue of IL-12 receptor b2, and
Y985 of the leptin receptor, showing that
suppression by SOCS3 is relatively
specific to STAT3 and STAT4. SOCS3
does not inhibit IL-10-mediated STAT3February 24, 2012 ª2012 Elsevier Inc. 157
Figure 1. Current Model of the Inhibition of JAKs by SOCS3
In a previous model, the KIR domain of SOCS3 (orange) functioned as pseudosubstrate for JAK kinase
(purple). In the current model proposed by Babon et al. (2012), based on a structural analysis of the
complex, SOCS3 binds to the surface of the JH1 domain, which contains a GQM motif and induces
a conformational change of the catalytic pocket, so as to block transfer of a phosphate group to the
substrate. KIR is involved in the binding of SOCS3 to JH1.
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to the IL-10 receptors (Yasukawa et al.,
2003). This is an important mechanism
for IL-6 and IL-10 to exhibit different
immunological effects.
This family has a conserved carboxy-
terminal 40 amino acid module known as
the SOCS box. The SOCS box interacts
with elongin B and elongin C and other
molecules that recruit E2 ubiquitin trans-
ferase (Babon et al., 2009). Thus SOCS
family proteins, as well as other SOCS-
box-containing molecules, function as
E3 ubiquitin ligases and mediate the
degradation of proteins that are associ-
ated with these family members through
their N-terminal regions.
In addition to their ability to suppress
signaling by ubiquitin-mediated degrada-
tion of the signaling complex, both
SOCS1 and SOCS3 are found to inhibit
JAK tyrosine kinase activity directly,
probably through their kinase inhibitory
region (KIR). KIR is composed of 12
amino acids and has been proposed to
function as a pseudosubstrate that is
essential for the suppression of cytokine
signals (Yasukawa et al., 1999). This
model is based on the following facts.
(1) KIR is essential for a high-affinity158 Immunity 36, February 24, 2012 ª2012 Ebinding of SOCS1 and SOCS3 to the
kinase domain (so called JH1) of JAKs,
but not necessary for binding to the
peptides containing phosphorylated tyro-
sine residues. (2) KIR peptide contains a
tyrosine residue that is a good substrate
of JAKs in vitro, but is never phosphory-
lated in vivo. (3) A high concentration of
KIR peptide inhibits JAK kinase activity,
which is apparently due to competitive
inhibition with substrates. However, other
possibilities such as direct inhibition of
JH1 by the KIR peptide (or by its modified
peptides) have been proposed (Doti et al.,
2011). Thus, the precise mechanisms of
suppression of kinase activity by KIR
remain to be clarified.
It has not been clear how SOCS3 in-
hibits JAK kinase after binding to gp130,
despite a low affinity of KIR peptide to
JH1. Because the whole SOCS3 (SH2-
domain+ESS+KIR) molecule can bind to
JH1 with high affinity, we proposed that
SOCS3 binds to the receptors first,
then moves to the kinase domain by
interacting with the phosphorylated acti-
vation loop though the SH2 domain, and
then KIR interacts with catalytic pocket
(Figure 1; Sasaki et al., 1999; Yoshimura
et al., 2007). A similar mechanism haslsevier Inc.been considered for SOCS1; it binds to
the IFN-g receptor (IFNGR1) first, then
binds to JAK2 and inhibits kinase activity.
However, it is still unknown how KIR
inhibits kinase activity.
To understand precise mechanism of
suppression of JAKs by SOCS1 and
SOCS3, X-ray or NMR structural analysis
of JAK and SOCS complex has been
anticipated. Previously, the X-ray crystal
structures of SOCS3 with gp130 phos-
phopetptide and SOCS2 with the Elon-
ginB-C complex were resolved (Babon
et al., 2006, 2009). Although these studies
defined the structures necessary for the
interaction with ElonginB-C or stability of
SOCS3, the function of KIR could not be
elucidated.
By using NMR spectrums of JAK2-JH1
and the SOCS complex in combination
with biochemistry, Babon et al. (2012)
now reveal how SOCS3 inhibits JAK
kinase. First, they show that SOCS3 binds
and directly inhibits the catalytic domains
of JAK1, JAK2, and TYK2, but not JAK3.
JAKs 1 and 2 and TYK2 (but not JAK3)
possess an evolutionarily conservedmotif
unique to JAKs, a GQM motif in the JAK
insertion loop. This motif is not the entire
binding surface on JAK-JH1, but is an
essential motif within the interaction
surface between JH1 and SOCS3. Im-
portantly, the gp130 phosphopeptide
induces a conformational change of the
KIR-ESS-SH2 domain of SOCS3 so that
SOCS3 can bind to the surface of JH1.
Then, kinetic experiments showed that
SOCS3 is a noncompetitive inhibitor of
JAK2-JH1 with respect to both ATP and
substrate, and that SOCS3 actually
increases ATPase activity of JH1. The
authors propose that SOCS3 specifically
inhibits the ability of JH1 to transfer phos-
phate to tyrosine but does not inhibit its
ability to hydrolyze ATP, and thus
increase the transfer of phosphate to
water (Figure 1).
This is a surprising and unique mecha-
nism we never expected. All other known
protein kinase inhibitors act by competi-
tive mechanisms, either by inhibiting
ATP or substrate binding directly. Their
model can explain a highly specific inhibi-
tion mechanism for JAK (except for JAK3)
by SOCS3 after binding to the receptor.
Because current JAK inhibitors are all
ATP analogs, this information will provide
clues to develop novel types of JAK
inhibitors. Importantly, ATP analog JAK
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were found to inhibit STAT3 less effi-
ciently than STAT1, STAT, and STAT6
(Yoshida et al., 2012). Thus, at low
concentrations, these inhibitors promote
T helper 17 (Th17) cell development by
suppressing Th1 and Th2 cell develop-
ment. Unlike in vitro, CP-690,550 seems
to inhibit JAK1 much less efficiently than
JAK3 in vivo (Yoshida et al., 2012). Thus,
new inhibitors specific to the GQM motif
with a non-ATP-competitive mechanism
could be more specific to JAK1 and
may inhibit STAT3 very efficiently. Such
a drug may be suitable for treatment of
Th17 cell-mediated diseases and cancers
where STAT3 plays critical roles.
Even though Babon et al. (2012)’s
study is extremely elegant, several ques-
tions remain to be solved. First, the inter-
action points between KIR and JH1 were
not clarified in this study because the
KIR region of SOCS3 is unstructured in
the absence of JAK2-JH1. Cocrystal
analysis may be necessary to resolve
this problem. Second, it remains to be
established whether this mechanism ofSOCS3 can be extended to SOCS1. The
SOCS1-IFNGR1 complex may inhibit
JH1 just like the SOCS3-gp130 complex.
However, apparently, the SOCS1 SH2
domain has a high affinity to the activation
loop of JH1 and can inhibit almost all cyto-
kine signaling by overexpression in vivo.
The interaction of SOCS1 with JH1 may
be different from that of SOCS3. The
mechanism of SOCS1 is a challenge of
structural biology because nobody has
been successful in obtaining recombinant
soluble and functional SOCS1 protein.
Third, the current findings should be
translated into drug discovery. In silico
structural modeling of JAKs and SOCS
may facilitate discovery of new drugs
that mimic SOCS.REFERENCES
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In this issue of Immunity, Silver et al. (2012) provide evidence that murine Toll-like receptor 9 (TLR9) expres-
sion and function in innate and adaptive immunity is controlled by the circadian cycle.Toll-like receptor 9 (TLR9) belongs to
the TLR family of pattern recognition
receptors (PRRs) that are important for
sensing evading pathogens via con-
served pathogen-associated molecular
patterns (PAMPs). The family of TLRs
consists of 13 members (TLR1 to TLR13)
that sense different PAMPs such as lipo-
polysaccharide, lipoproteins, flagellin,
and nucleic acids (Iwasaki and Medzhi-
tov, 2004). TLR9 is part of a subgroup of
TLRs that is expressed in endosomal
vesicles and recognizes bacterial and
viral DNA with a sequence motif contain-ing the dinucleotide CpG. Importantly,
ligand sensing by TLR9 leads to subse-
quent production of type I interferon,
proinflammatory cytokines and upregula-
tion of costimulatory molecules, signals
essential for initiating and directing an
antigen-driven adaptive immune re-
sponse (Iwasaki and Medzhitov, 2004;
Kumagai et al., 2008). Synthetic CpG-
containing deoxynucleotides that mimic
microbial DNA are undergoing clinical
testing as adjuvant in vaccines and as
immunomodulator against infection or
for the treatment of cancer and allergy(Jurk and Vollmer, 2007). However, under
certain circumstances such as enhanced
DNA uptake, non-CpG-containing DNA
or self-DNA can also activate TLR9 and
induce or sustain certain autoimmune
diseases such as systemic lupus erythe-
matosus (SLE). Accordingly, self-DNA-
antibody complexes trigger TLR9 in SLE
and lead to the production of type I inter-
feron, which is involved in pathogenesis of
the disease. Thus, TLR9 antagonists are
also currently evaluated for therapeutic
use, especially for the treatment of SLE
(Marshak-Rothstein, 2006).February 24, 2012 ª2012 Elsevier Inc. 159
